Infigratinib

An oral medication to treat children with achondroplasia has received breakthrough therapy designation from the FDA, BridgeBio Pharma announced.

Wastage from dose reduction or discontinuation of the most common oral anticancer drugs costs a mean of $4,290 per patient, results of a retrospective study showed.

The FDA granted accelerated approval to infigratinib for previously treated locally advanced or metastatic cholangiocarcinoma that harbors FGFR2 fusion or rearrangement.

The FDA granted priority review designation to infigratinib for the treatment of cholangiocarcinoma, according to the agent’s manufacturer.